Author

P. J. C. Lin

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 5 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:host-pathogen & immune response· 4 Organism:mouse· 4 Research Focus:cell signaling & trafficking· 2 Research Focus:cell type annotation· 2 Assay:proteomics· 2 Approach:deep learning· 1 Research Focus:differential expression· 1

Frequent Co-Authors

H. Muramatsu· 3 shared N. Pardi· 3 shared Y. K. Tam· 3 shared D. Weissman· 2 shared A. A. Cohen· 1 shared A. Cremonesi· 1 shared A. Dimitrakakis· 1 shared A. Fiore-Gartland· 1 shared

Activity by Year

2020-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 19 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

H. Muramatsu

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Mosaic sarbecovirus nanoparticles elicit cross-reactive responses in pre-vaccinated animals

A. A. Cohen, J. R. Keeffe, A. Schiepers, S. E. Dross, A. J. Greaney, A. V. Rorick, H. Gao, P. N. P. Gnanapragasam, C. Fan, A. P. West, A. I. Ramsingh, J. H. Erasmus, J. D. Pata, H. Muramatsu, N. Pardi, , P. J. Bjorkman

The paper shows mosaic-8b nanoparticles induce broader cross-reactive antibodies than homotypic ones, even in pre-vaccinated animals, suggesting potential for improved vaccine design against emerging sarbecoviruses.

bioRxiv · Feb 8, 2024Immunology

Treatment of a genetic liver disease in mice through transient prime editor expression

T. Rothgangl, E. I. Ioannidi, Y. Weber, A. Talas, D. Boeck, M. Matsushita, E. A. Villiger, L. Schmidheini, J. Moon, P. J. C. Lin, S. H. Y. Fan, K. F. Marquart, C. Schwerdel, N. Rimann, E. Faccin, , G. Schwank

This paper demonstrates transient prime editor expression in mice to correct a genetic liver disease, reducing blood phenylalanine levels below the therapeutic threshold.

bioRxiv · Jan 22, 2024 · PreprintBioengineering

The Regulation of Nucleic Acid Vaccine Responses by the Microbiome

A. M. F. Johnson, K. Hager, M.-G. Alameh, P. Van, N. Potchen, K. Mayer-Blackwell, A. Fiore-Gartland, S. Minot, P. J. C. Lin, Y. K. Tam, D. Weissman, J. G. Kublin

This study shows the microbiome affects nucleic acid vaccine responses differently depending on the vaccine type, enhancing mRNA-LNP responses but suppressing DNA-prime/DNA-protein-boost responses.

bioRxiv · Feb 18, 2023Immunology

Multivalent Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccines Demonstrate a Greater Breadth in T cell but not Antibody Responses

S. R. Permar, H.-Y. Wang, L. Li, C. S. Nelson, R. Barfield, S. Valencia, C. Chan, H. Muramatsu, P. J. C. Lin, N. Pardi, Z. An, D. Weissman

This study evaluates multivalent HCMV gB mRNA vaccines in rabbits, finding increased T cell responses but no improvement in antibody breadth.

bioRxiv · Nov 23, 2022 · PreprintImmunology

A pan-variant mRNA-LNP T cell vaccine protects HLA transgenic mice from mortality after infection with SARS-CoV-2 Beta

B. Carter, P. Huang, G. Liu, Y. Liang, P. J. C. Lin, B.-H. Peng, L. McKay, A. Dimitrakakis, J. Hsu, V. Tat, P. Saenkham-Huntsinger, J. Chen, C. Kaseke, G. D. Gaiha, Q. Xu, , D. K. Gifford

A T cell vaccine based on conserved epitopes protects HLA transgenic mice from SARS-CoV-2 Beta variant mortality without inducing neutralizing antibodies.

bioRxiv · Sep 23, 2022Immunology

Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine induces equivalent preclinical antibody titers and viral neutralization to recovered COVID-19 patients

P. F. McKay, K. Hu, A. K. Blakney, K. Samnuan, C. R. Bouton, P. Rogers, K. Polra, P. J. C. Lin, C. Barbosa, Y. Tam, R. J. Shattock

bioRxiv · Apr 22, 2020 · PreprintImmunology